Eli Lilly | LLY - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
AbbVie USD 41.64B 458M 2026-06
Abbott USD 18.38B 1.88B 2026-03
ALKERMES USD 662.09M 62.59M 2026-06
Amgen USD 25.5B 547M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
Baxter International USD 3.59B 102M 2026-06
Biogen USD 3.92B 918.2M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Coherus Biosciences USD 75.51M 56.82M 2026-06
Drreddys Laboratories INR 167.57B 165.8B 2026-03
Eli Lilly USD 47.74B 11.11B 2026-06
Gilead Sciences USD 11.02B 1.54B 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
Glaxosmithkline GBP 22.43B 6.39B 2026-03
J&J USD 54.9B 2.82B 2026-06
Medtronic USD 9.5B 440M 2025-12
Merck USD 27.73B 786M 2026-06
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06
Novartis USD 31.37B 4.1B 2026-03
Novo Nordisk DKK 239.08B 13.92B 2026-06
Perrigo USD 1.05B 57.2M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Phibro Animal Health USD 281.87M 500K 2026-03
Prestige Brands USD 153.81M 32.88M 2026-06
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sanofi EUR 31.93B 1.92B 2026-06
Sanofi EUR 30.01B 1.66B 2026-03
United Therapeutics USD 607.8M 8.7M 2026-06
Zoetis USD 2.06B 8M 2026-06